Halogenated salicylanilides for treating clostridium infections

ABSTRACT

The present invention relates to halogenated salicylanilides, or pharmaceutically acceptable salts or esters thereof, for use in the treatment of an infection in a subject caused by Clostridium bacteria, particularly a C. difficile infection. The halogenated salicylanilides are expected to be useful in the treatment of C. difficile associated diseases including C. difficile associated diarrhoea and C. difficile associated colitis.

This application claims priority to U.S. application Ser. No.15/576,220, filed Nov. 21, 2017, which is the national stage entry ofPCT Application No. PCT/EP2016/061968, filed May 27, 2016, which claimspriority to Great Britain Application No. 1509326.3, filed May 29, 2015.The entire contents of these applications are incorporated herein byreference in their entirety for all purposes.

NOVEL USE

This invention relates to halogenated salicylanilides for use in theprevention or treatment of infections caused by Clostridium bacteria,particularly Clostridium difficile.

BACKGROUND OF THE INVENTION

Clostridium is a genus of spore forming Gram-positive bacteria that growunder anaerobic conditions comprising more than 100 species. There arefour main species responsible for diseases in humans and otherwarm-blooded animals: C. botulinum, an organism producing a toxin infood or wounds that causes botulism; C. difficile, which can causepseudomembraneous colitis, toxic megacolon and antibiotic associateddiarrheas; C. tetani, which is the causative organism of tetanus; and C.perfringens, which can cause enterotoxemia, necrotizing enteritis, andgas gangrene.

C. perfringens is ubiquitous in the environment and is found in soil,dust, raw ingredients such as spices used in food processing, and in theintestines of humans and animals. It produces over 15 different toxinsresulting in various enteric conditions. C. perfringens infections canalso cause gut health problems in broiler flocks with significantnegative economic consequences.

C. difficile is an opportunistic gram positive, anaerobic, spore formingbacillus, and causes Clostridium difficile infections (CDI) such asantibiotic-associated diarrhoea (CDAD) and colitis which burdenshealthcare systems across the globe. In the last decade, rates of C.difficile infections have increased dramatically, particularlyhospital-acquired infection (nosocomial infection), resulting inincreased morbidity, an increased incidence of complications requiringcolectomy, and rising mortality.

It is estimated that 3 to 15% of the normal population is infected withC. difficile. However, rates of infection are much higher inhospitalised patients. C. difficile colonises the intestine and in manysubjects infected the bacteria lives in equilibrium with other gut floraand is asymptomatic. However, if the homoeostasis of the normalintestinal flora is disturbed, for example as a result of previousantibiotic use, the use of drugs which alter the gastric pH (for exampleproton pump inhibitors), or gastrointestinal surgery, symptomatic CDIcan arise as a result of the proliferation of the C. difficile in theintestine. Toxins produced by the C. difficile disrupt the colonicepithelium, leading to an inflammatory response and clinical symptomsvarying from mild diarrhoea to severe life-threatening pseudomembranouscolitis.

C. difficile bacteria produce toxins, which can cause inflammation anddamage to the lining of the lower gastro-intestinal tract, including thecolon. There are a number of different strains of C. difficile, some ofwhich can cause more serious illnesses than others. Strain NAP1/027/BI027 (NAP1/027) produces particularly high levels of toxins and isassociated with particularly severe CDI and high levels of mortality.

C. difficile infections are particularly associated with the clinicaluse of broad spectrum antibiotics, for example clindamycin,cephalosporins and amoxicillin-clavulinic acid). Fluoroquinoloneantibiotics have been identified as a particular risk factor for CDI.Antibiotics commonly used to treat a primary infection in a subject (forexample a urinary infection, a skin infection or other infection), killthe bacteria that cause the primary infection. However, they may alsokill many of the bacteria present in the flora of the GI tract. BecauseC. difficile bacteria are not affected by many commonly used antibioticsthis can result in the proliferation of C. difficile in the intestineand the presence of high levels of associated toxins resulting in theemergence of symptoms of a CDI.

C. difficile infection is the most common infectious cause of nosocomialdiarrhoea in elderly patients, accounting for 15% to 25% of all cases ofantibiotic-induced diarrhoea. Patients undergoing total jointarthroplasty are at particular risk of CDI because of the advanced ageof the patients, the use of prophylactic antibiotic coverage in theperioperative period, multiple comorbid conditions, and length ofhospital stay required for recovery.

The treatment of C. difficile infections depends on the severity of theassociated symptoms or disease. Generally asymptomatic infections arenot treated. However, if symptoms develop treatments are generallyrequired to reduce the symptoms and prevent the infection fromworsening.

Generally a first step in the treatment of CDI is the cessation of theinciting antibiotic. Treatment with concomitant antibiotics (i.e.antibiotics other than those given to treat C. difficile infection) isassociated both with significant prolongation of diarrhoea and with anincreased risk of recurrent CDI. If concomitant antibiotics areessential for treatment of the primary infection, it is generallyprudent, if possible, to use an antibiotic therapy that is lessfrequently implicated in antibiotic-associated CDI, such as parenteralaminoglycosides, sulfonamides, macrolides, vancomycin, or tetracycline(Läkartidningen, 103(46), 2006).

C. difficile infection, such as CDAD is usually treated withmetronidazole or oral vancomycin. A new antibiotic against C. difficilehas recently been approved, fidaxomicin (OPT-80, PAR-101), a macrocyclicantibiotic. In phase III clinical trials, fidaxomicin was non-inferiorto vancomycin in achieving clinical cure of CDAD. Fidaxomicin treatmentwas also superior to vancomycin in preventing recurrence of CDAD. Theseresults, combined with the ease of administration and a somewhat bettersafety profile has made fidaxomicin an attractive treatment option fortreating CDAD. (Louie, T. J., Miller, M. A., Mulvane, K. M., Weiss, K.,Lenten, A. Shoe, Y. K. (2011). Fidaxomicin versus Vancomycin forClostridium difficile infection. New England Journal of Medicine, 364,422-431). However, resistance towards metronidazole, vancomycin andfidaxomicin has been observed.

Rifamycins and derivatives, for example rifampicin and rifaximin, havebeen successfully used to treat recurrent CDI. However, rapidspontaneous resistance evolution has also been observed with this classof antibiotic and the spread of, for example rifampicin-resistant C.difficile in hospitals is an increasing concern.

Teicoplanin (although not widely available and expensive) is anotherantibiotic with high reported efficacy against CDI, and limited datasuggest that it may be effective in recurrent CDI.

Patients who have had one CDI are at risk of recurrence of theinfection. The rate of recurrent CDI (RCDI) is estimated to be 15% to30%. Patients with recurrent C. difficile infections in hospitals andthe community constitute an increasing treatment problem. Whilst mostpatients with a first infection respond to either metronidazole or oralvancomycin, current therapeutic approaches to recurrent C. difficileinfections are prone to failure, increasing the risk of antibioticresistance emerging. Most treatment guidelines recommend prolonged oralvancomycin pulse and/or tapering dosage regimens. However, evidencesupporting the effectiveness of such dosage regimens is limited.

The spores formed by C. difficile are thought to be the primarymechanism for the transmission or spread of infection. Additionallyspores present in the colon of a patient may be responsible forrecurrence of C. difficile infections, even after elimination of thebacterial with antibiotic treatment. Fidaxomycin has been shown toinhibit C. difficile spore formation (Babakhani et al, S162 CID 2012:55(suppl 2)). There is however a need for additional agents that caninhibit spore formation and thus minimise the risk of transmissionand/or recurrence of C. difficile infections.

U.S. Pat. No. 8,618,100 discloses chromanyl derivatives described ashaving antibacterial activity against Clostridium bacteria, inparticular Clostridium perfringens.

PCT patent application WO2008/039640 discloses the compound5-[3-((R)(+)-6,8-dibromo-chroman-4-ylamino)-propylamino]-4H-thieno[3,2-b]pyridine-7-one,which is also known as REP3123, and its antibacterial activity againstClostridium difficile. In vitro tests of the antibacterial activity ofthe REP3123 compound demonstrate that said compound is active againstbacteria of the Clostridium genus however REP3123 also has antibacterialactivity against a wide variety of bacteria that are present in the gut.

U.S. Pat. No. 8,796,292 discloses that certain7-substituted-2-(benzylamino)-6-oxopurines have potent activity againstthe growth of the intestinal anaerobe C. difficile, but weak activityagainst other, intestinal Gram-positive anaerobes. The compounds aredescribed to be useful in reducing the likelihood of developing or totreat C. difficile infections.

PCT application WO2014135891 describes the rectal administration ofcompositions comprising fidaxomicin. The compositions are described asuseful for the treatment or maintenance of remission of infections suchas diarrhea caused by C. difficile.

PCT application WO2012/050826 describes the use of reutericyclin orreutericyclin analogs in order to kill C. difficile organisms and thusalleviate the signs and symptoms of C. difficile infection.

There is however a need for new treatments for C. difficile.

Halogenated salicylanilides such as niclosamide, closantel andrafoxanide, are important anthelmintics that are used extensively in thecontrol of Haemonchus spp. and Fasciola spp. infestation in sheep andcattle, and Oestrus ovis in sheep.

Niclosamide is commercially available in a number of formulationsincluding, but not limited to Bayer73®, Bayer2353®, Bayer25648®,Bayluscid®, Baylucide®, Cestocid®, Clonitralid, Dichlosale®, Fenasal®,HL 2447®, Iomesan®, Iomezan®, Manosil®, Nasemo®, Niclosamid®, Phenasal®,Tredemine®, Sulqui®, Vermitid®, Vermitin® and Yomesan®.

Niclosamide has been proposed as a possible systemic treatment forchronic lung infections caused by the proteobacterium Pseudomonasaeruginosa and the actinobacterium Mycoplasmum tuberculosis (F. Imperiet al., Antimicrobial, Agents and Chemotherapy, 557(2), 996-1005(2013)).

J. Vinsova et al. (Molecules, vol. 12, no. 1, pp. 1-12, 2007; Bioorganicand Medicinal Chemistry Letters, vol. 19, no. 2, pp. 348-351, 2009;European Journal of Medicinal Chemistry, vol. 45, no. 12, pp. 6106-6113,2010) describe certain antibacterial activity of salicylanilides,however, there is no disclosure of the treatment of CDI.

Ghazi et al. (Zentralbl. Mikrobiol. 141 (1986), 225-232) have tested theantibacterial effect and toxicity of synthesized salicylanilidederivatives against Escherichia coli, Bacillus subtilis, Pseudomonasaeruginosa and Staphylococcus aureus.

M. J. Macielag et al. tested for antibacterial activity of closantel andrelated derivatives against the drug-resistant organisms,methicillin-resistant Staphylococcus aureus (MRSA) andvancomycin-resistant Enterococcus faecium (VREF) (J. Med. Chem., 41(16),2939-45 (1998)).

D. J. Hlasta at al. found that closantel had antibacterial activityagainst drug resistant S. aureus and E. faecium (Bioorg. Med. Chem.Letters, 8(14), 1923-28 (1998)).

R. Rajamuthiah at al. (PloS One, 2014, 9(2): e89189) identifiedclosantel as a hit in a high throughput liquid screening assay and foundanti-staphylococcal activity of closantel against vancomycin-resistantS. aureus isolates and other Gram-positive bacteria.

R. Rajamuthiah at al. (PloS One, 2015, 10(4):e0124595) describe thatniclosamide and oxyclosanide have activity against MRSA.

Pauk at al. Bioorg. & Med. Chem. 23, 6574-6581 (2013), discloses thein-vitro anti-microbial activity of certain halogenated salicylanilidesand derivatives.

WO 2008/155535 describes the use of halogenated salicylanilides for thetreatment of acne resulting from propioni bacterial infection.

BRIEF SUMMARY OF THE DISCLOSURE

It has been found that halogenated salicylanilides (for exampletetrachlorosalicylanilide, closantel, rafoxanide, oxyclozanide,resorantel, clioxanide, dibromosalan, tribromosalan and niclosamide) areactive against Clostridium bacteria, particularly C. difficile and maybe useful in treating and/or preventing or reducing Clostridiuminfection and possible reoccurrence of the infection. Use of halogenatedsalicylanilides may also reduce the rate of developing antibioticresistance compared to known antibiotics used for the treatment ofClostridium infections.

In accordance with the present invention, there is provided ahalogenated salicylanilide, or a pharmaceutically acceptable salt orester thereof, for use in the treatment of an infection in a subjectcaused by Clostridium bacteria.

The infection may be caused by a Clostridium bacteria selected from forexample, C. perfringens, C. difficile, C. botulinum, C. tetani, C.absonum, C. argentinense, C. baratii, C. bifermentans, C. beijerinckii,C. butyricum, C. cadaveris, C. camis, C. celatum, C. clostidiolfore, C.cochlearium, C. cocleatum, C. fallax, C. ghonii, C. glycolicum, C.haemolyticum, C. hastifbrme, C. histolyticum, C. indolis, C. innocuum,C. irregulare, C. leptum, C. limosum, C. malenominatum, C. novyi, C.oroticum, C. oedematiens, C. paraputrificum, C. pilifonnrme, C.putrefasciens, C. ramosum, C. septicum, C. sordelii, C. sphenoides, C.spiroforme, C. sporogenes, C. subterminale, C. symbiosum, C. tertium orC. tetani.

In one embodiment the bacteria causing the infection is not C.perfringens.

The infection is particularly an infection caused by C. difficile.

Infection by Clostridium difficile may result in a C. difficile diseasein the subject. The C. difficile disease may be, for example, diarrhoea,colitis (including pseudomembranous colitis) or toxic megacolon. The C.difficile infection may be C. difficile associated diarrhoea. The C.difficile infection may be C. difficile associated colitis, for examplepseudomembranous colitis. The C. difficile infection may be C. difficileassociated bloating. The C. difficile infection may be C. difficileassociated abdominal pain.

C. difficile infection in a subject generally arises as a result of thetreatment of an infection with an antibiotic. The use of antibiotics totreat an infection will kill the organism causing the underlyinginfection. However, the antibiotic may also kill many of the bacteriapresent in the GI tract. The disruption of the normal gut flora canresult in the proliferation of the C. difficile and emergence of effectsof the infection including diarrhoea and colitis. Accordingly it may bethat the halogenated salicylanilide is for use in the treatment of anantibiotic induced Clostridium infection, particularly an antibioticinduced C. difficile infection.

It may be that the antibiotic responsible for the antibiotic inducedClostridium infection is an antibiotic other than a halogenatedsalicylanilide. It may be that the antibiotic responsible for inducingthe Clostridium infection is an antibiotic used to treat a primaryinfection in the body other than a Clostridium infection (e.g. otherthan a C. difficile infection). For example, the primary infection maybe a skin infection, a urinary tract infection, a lung infection or abone infection. The antibiotic responsible for inducing the infectionmay be a broad spectrum antibiotic which may be active against Grampositive and/or Gram negative organisms. The antibiotic may be selectedfrom clindamycin, a cephalosporin (for example cefotaxime andceftaidime), ampicillin, amoxicillin and a quinolone (for example afluoroquinolone, optionally ciprofloxaxin or levofloxacin). For example,the antibiotic induced C. difficile infection may be caused by afluoroquinoline antibiotic, including but not limited to ciprofloxaxinor levofloxacin.

Although C. difficile infections are generally caused by prior use ofantibiotics to treat an underlying infection, C. difficile infectionsmay also be arise without the prior use of an antibiotic. For example, areduction in the acidity of the stomach can result in colonization ofthe normally sterile upper gastrointestinal tract. The use of gastricacid suppressive agents, such as proton pump inhibitors (PPIs) andhistamine H2-receptor antagonists (H2RAs) may therefore be associatedwith an increased risk of C. difficile colonization and subsequentdevelopment of CDAD. PPIs include, but are not limited to, omeprazole(Losec, Prilosec, Zegerid), lansoprazole (Prevacid, Zoton, Inhibitol),esomeprazole (Nexium), pantoprazole (Protonix, Somac, Pantoloc,Pantozol, Zurcal, Pan) and rabeprazole (Rabecid, Aciphex, Pariet,Rabeloc). H2RAs include, but are not limited to, cimetidine (Tagamet),ranitidine (Zinetac, Zantac), famotidine, (Pepcidine, Pepcid),roxatidine (Roxit) and nizatidine (Tazac, Axid). It may be that thehalogenated salicylanilide is for use in the treatment of a Clostridiuminfection (for example a C. difficile infection) induced by a gastricacid suppressive agent. Accordingly it may be that the halogenatedsalicylanilide is for use in treating a Clostridium infection in asubject that is or has been treated with a gastric acid suppressiveagent, for example a PPI. Accordingly the halogenated salicylanilide maybe for use in treating a Clostridium infection in a subject treated witha H2RA.

C. difficile infection associated disease may also arise spontaneously,particularly when the subject is infected with certain stains of C.difficile, for example an infection caused by the NAP1/027/B strainwhich produces high levels of Toxin A, Toxin B and other toxins.

The halogenated salicylanilide may be used as the first line treatmentof a Clostridium infection, for example a C. difficile infection. By“first-line” treatment is meant the first treatment of the Clostridiuminfection. In the first line treatment the Clostridium infection has notbeen treated with an antibiotic active against the Clostridiuminfection, for example, metronidazole, vancomycin, fidaxomicin or arifamycin such as rifaximin. Accordingly, it may be that the halogenatedsalicylanilide is for use in the treatment of a Clostridium infection(for example C. difficile infection), wherein the infection has not beentreated with an antibiotic prior to administration of the halogenatedsalicylanilide to the subject.

The halogenated salicylanilide may be used to treat a recurrentClostridium infection (e.g. a C. difficile infection), for example aClostridium infection which has recurred following prior treatment ofthe subject with an antibiotic (or other agent) other than a halogenatedsalicylanilide. For example, the halogenated salicylanilide may be usedto treat a Clostridium infection (for example a C. difficile infection)which has recurred in a subject following prior treatment of the subjectwith an antibiotic selected from metronidazole, vancomycin, fidaxomicinand a rifamycin such as rifaximin. Suitably an antibiotic selected frommetronidazole, vancomycin and fidaxomicin.

The halogenated salicylanilide may be used to treat a Clostridiuminfection (for example a C. difficile infection) which is refractory(for example non-responsive) to treatment with an antibiotic (or otheragent) other than a halogenated salicylanilide. For example, thehalogenated salicylanilide may be used to treat a refractory Clostridiuminfection (for example a C. difficile infection) in a subject.Accordingly, the halogenated salicylanilide may be for use in thetreatment of a Clostridium infection (e.g. C. difficile) that isrefractory to a prior antibiotic treatment other than a halogenatedsalicylanilide. For example the halogenated salicylanilide may be usedto treat a C. difficile in a subject, wherein the C. difficile isrefractory to treatment of the subject with an antibiotic selected frommetronidazole, vancomycin, fidaxomicin and a rifamycin such asrifaximin.

It may be that the halogenated salicylanilide is used to treat aClostridium infection (for example a C. difficile infection) which isresistant to an antibiotic agent used to treat the Clostridiuminfection. Accordingly there is provided a halogenated salicylanilide,or a pharmaceutically acceptable salt thereof, for use in the treatmentof a Clostridium infection (for example a C. difficile infection) whichis resistant to an antibiotic agent other than the halogenatedsalicylanilide.

It may be that the Clostridium (for example a C. difficile) is resistantto an antibiotic agent approved by the US FDA or European MedicinesAgency prior to 27 May 2016, preferably an antibiotic approved for usein the treatment of a Clostridium infection (for example a C. difficileinfection). It may be that the Clostridium (for example a C. difficile)which is resistant to an antibiotic other than the halogenatedsalicylanilide. It may be that the Clostridium (for example a C.difficile) which is resistant to an antibiotic selected from apenicillin, a cephalosporin, a carbapenem, a monobactam (for example aβ-lactam antibiotic), a fusidane, a fluoroquinolone, a tetracycline, aglycylcycline, phenicol (for example chloramphenicol), a macrolide, amacrocyclic (for example fidaxomicin), a rifamycin, a ketolide, alincosamide, an oxazolidinone (for example cadazolid), an aminocyclitol,a polymyxin, a glycopeptide, an aminoglycoside, a lipopeptide, anantimycobacterial, a nitroimidazole, bacitracin, mupiricin, apleuromutilin, a rifamycin, a sulphonamide and trimethoprim.

It may be that the Clostridium (for example a C. difficile) is resistantto an antibiotic selected from a nitroimidazole, for examplemetronidazole; a benzimidazole, for example ridinilazole (SMT19969); aglycopeptide, for example vancomycin; a macrocyclic antibiotic, forexample fidaxomicin; an oxazolidinone, for example cadazolid; alipopeptide, for example surothromycin or daptomycin; a glycylcycline,for example tigecycline; a DNA Minor Groove Binder (for exampleMGB-BP-3) a glycolipodepsipeptide (for example ramoplanin); CRS3123 (aMethionyl-tRNA synthetase (MetRS) inhibitor, Crestone Inc); and arifamycin such as rifaximin. For example it may be that the Clostridium(for example a C. difficile) is resistant to an antibiotic selected frommetronidazole, vancomycin, fidaxomicin and a rifamycin (e.g. rifaximin).

The C. difficile infection may be any strain of C. difficile for examplethe C. difficile strains shown in Table 1 below, in which the NCTCnumber is the UK National Collection of Type Culture reference number.

TABLE 1 NCTC no. Ribotype and Toxin Status NCTC 11209 (T) Type strain,PCR-ribotype 001 reference strain NCTC 11204 PCR-ribotype 001, toxin Aand B positive NCTC 11205 PCR-ribotype 001, toxin A and B positive NCTC11207 PCR-ribotype 001, toxin A and B positive NCTC 11208 PCR-ribotype001, toxin A and B positive NCTC 11223 PCR-ribotype 001, toxin A and Bpositive NCTC 11382 PCR-ribotype 001, toxin A and B positive NCTC 12729PCR-ribotype 002, toxin A and B positive NCTC 13287 PCR-ribotype 017,toxin A negative, toxin B positive NCTC 13307 PCR-ribotype 012, toxin Aand B positive NCTC 13404 PCR-ribotype 106 reference strain, toxin A andB positive NCTC 13366 PCR-ribotype 027 reference strain, toxin A and Bpositive T = Type Strain

It may be that the C. difficile infection is a strain of C. difficilewhich produces high levels of Toxin A (entero toxin) and/or Toxin B(cytotoxin). For example it may be that the C. difficile infection is astrain of C. difficile which produces higher levels of Toxin A than NCTC11209 (T). It may be that the C. difficile infection is a strain of C.difficile which produces higher levels of Toxin B than NCTC 11209 (T).It may be that the C. difficile infection is a strain of C. difficilewhich produces higher levels of Toxin A and Toxin B than NCTC 11209 (T).

The C. difficile infection may be the hyper-virulent BI/NAP1 (also knownas ribotype 027, NAP1/027/BI or NCTC 13366) strain which shows increasedToxin A (entero toxin) and Toxin B (cytotoxin) production as well as theproduction of additional novel binary toxins. Accordingly, thehalogenated salicylanilide may be for use in the treatment of a C.difficile caused by the NAP1/027/BI C. difficile strain.

C. difficile is an anaerobe and as such the bacteria itself is generallynot the primary mechanism for the transmission of infection, because thebacterial is not viable in aerobic conditions. However, C. difficileproduces spores which are metabolically dormant and very stable. Sporesshed in faecal matter are therefore very difficult to eradicate and maypersist in the environment for prolonged periods of time, because theyare resistant to heat and common cleaning and sterilisation chemicals.The spores represent the primary mechanism for the transmission of C.difficile infections. Current treatments for C. difficile, for example,metronidazole, vancomycin and rifamycins are effective against C.difficile. However, these compounds have limited effects on sporulationand may not effective in preventing transmission of infections by thespores. Fidaxomicin has been shown to be superior to metronidazole,vancomycin, and rifaximin in inhibiting sporulation and as such iscurrently considered to be the “gold-standard” treatment of C. difficileinfections because of its potential to also inhibit transmission ofinfection.

As illustrated in the Examples below, halogenated salicylanilides (forexample rafoxanide) are effective inhibitors of C. difficilesporulation. In the study performed in the Examples, rafoxanide was moreeffective than fidaxomicin in inhibiting sporulation. Accordingly it isexpected that the halogenated salicylanilides will provide an effectivetreatment which both kills the C. difficile bacteria and inhibits C.difficile sporulation. The halogenated salicylanilides are thereforeexpected to provide an effective treatment of the initial C. difficileinfection and also prevent or minimise the risk of transmission orspread of infection, for example spread of infection in a community orhospital environment.

Accordingly there is provided a halogenated salicylanilide, or apharmaceutically acceptable salt or ester thereof (for examplerafoxanide), for use in preventing or inhibiting sporulation of C.difficile.

Also provided is a halogenated salicylanilide, or a pharmaceuticallyacceptable salt or ester thereof (for example rafoxanide), for use inpreventing or inhibiting transmission or spread of a C. difficileinfection.

Also provided is a halogenated salicylanilide, or a pharmaceuticallyacceptable salt or ester thereof (for example rafoxanide), for use in amethod of preventing or inhibiting transmission or spread of a C.difficile infection, the method comprising administering the halogenatedsalicylanilide, or a pharmaceutically acceptable salt or ester thereofto a subject with a C. difficile infection.

A common problem associated with C. difficile infection is therecurrence of the infection following initial antibiotic treatment.Often a patient will respond well to the initial antibiotic treatmentand will be symptom free for a period of time. However, in many patientsrecurrence of the infection is common and is often more severe than theinitial infection (Louie T J, et al. N. Eng. J. Med 2011; 364: 422-31).Mortality rates increase as the frequency of recurrent infectionincreases. A primary factor in the recurrence of infection is thought tobe spores residing in the GI tract, particularly in the colon of apatient who has previously had a C. difficile infection. Spores presentin the colon of a patient that has been infected with C. difficile andcan persist there in a dormant state for long periods of time. Uponactivation the spores result in recurrence of the infection. Thesporulation inhibitory properties of the halogenated salicylanilides aretherefore expected to be beneficial in the prevention or reduction ofthe recurrence of C. difficile infection by reducing or eliminatingspore formation in a patient infected with C. difficile.

Accordingly also provided is a halogenated salicylanilide, or apharmaceutically acceptable salt or ester thereof (for examplerafoxanide), for use in a method of preventing or inhibiting recurrenceof C. difficile infection in a subject with a C. difficile infection,the method comprising administering the halogenated salicylanilide, or apharmaceutically acceptable salt or ester thereof to the subject.

Halogenated Salicylanilides

Halogenated salicylanilides are also known as2-hydroxy-N-phenylbenzamides or 2-hydroxybenzanilides. Salicylanilidesare weakly acidic phenolic compounds. Halogenated salicylanilides aresalicylanilides substituted by at least one halo group. The compoundswere originally developed as fungicides for topical use and asantimicrobial agents in soaps. Later these compounds were shown topossess potent antihelmintic activity of which niclosamide,tribromosalan and clioxanide were some of the first agents to be used. Awide range of halogenated salicylanilide derivatives are known. Anyhalogenated salicylanilide possessing antibacterial activity againstClostridium may be used in the present invention. For example, thehalogenated salicylanilide may be any of the niclosamide analoguesdescribed in WO 2008/021088, which are incorporated herein by referencethereto.

The halogenated salicylanilide may be a halogenated salicylanilide ofthe formula (I):

wherein

X is O or S;

R¹ and R² are at each occurrence independently selected from halo;R³ and R⁴ are at each occurrence independently selected from H, C₁₋₆alkyl, —OR^(A1), —NO₂ and —CN;R⁵ is H or -L¹-R⁷;R⁶ is H or —C(O)R^(A2);L¹ is selected from a bond, O, S, or —(CR^(A3)R^(B))_(o)—, wherein o is1 or 2;R⁶ is phenyl, unsubstituted or substituted with 1, 2, or 3 groupsselected from halo, C₁₋₄ alkyl, —OR^(A4), —NO₂ and —CN;R^(A1), R^(A2), R^(A3) and R^(A4) are at each occurrence independentlyselected from H and C₁₋₄ alkyl;R^(B) is at each occurrence selected from H, C₁₋₄ alkyl and —CN;n and p are each independently selected from 0, 1, 2, 3 or 4, with theproviso that n+p is at least 1;t and v are independently selected from 0, 1 and 2;or a pharmaceutically acceptable salt, or ester thereof.

The halogenated salicylanilide of formula (I) may be of the formula(II), or a pharmaceutically acceptable salt, or ester thereof.

The following statements in the numbered paragraphs below apply tocompounds of the formulae (I) or (II). These statements are independentand interchangeable. In other words, any of the features described inany one of the following statements may (where chemically allowable) becombined with the features described in one or more other statementsbelow. In particular, where a compound is exemplified or illustrated inthis specification, any two or more of the statements below whichdescribe a feature of that compound, expressed at any level ofgenerality, may be combined so as to represent subject matter which iscontemplated as forming part of the disclosure of this invention in thisspecification.

1. X is O.

2. R¹ and R² are at each occurrence independently selected from fluoro,chloro, bromo and iodo.

3. R¹ and R² are at each occurrence independently selected from chloro,bromo and iodo.

4. R¹ is chloro.

5. R¹ is bromo.

6. R¹ is iodo.

7. R² is chloro.

8. R² is bromo.

9. R² is iodo.

10. R³ and R⁴ are at each occurrence independently selected from H, C₁₋₄alkyl, —OR^(A1), —NO₂ and —CN.

11. R³ and R⁴ are at each occurrence independently selected from H, C₁₋₄alkyl, —OR^(A1) and —NO₂.

12. R³ and R⁴ are at each occurrence independently selected from H, C₁₋₄alkyl, —OH, —OMe, —NO₂ and —CN, for example H, C₁₋₄ alkyl, —OH or —NO₂.

13. R⁵ is H.

14. R⁵ is -L¹-R⁷.

15. L¹ is selected from —O—, —CH₂— and —CH(CN)—, for example —O— or—CH(CN)—.

16. R⁷ is phenyl, unsubstituted or substituted with 1, 2, or 3 groupsselected from halo, C₁₋₄ alkyl and —CN

17. R⁷ is phenyl unsubstituted or substituted with 1, 2, or 3 groups(for example 1 or 2 groups) selected from halo.

18. R⁷ is unsubstituted phenyl.

19. L¹ is selected from —O— and —CH(CN)—; and R⁷ is phenyl unsubstitutedor substituted with 1, 2, or 3 groups selected from halo.

20. R⁶ is H.

21. R⁶ is —C(O)R^(A), for example —C(O)CH₃.

22. t=0 or 1.

23 t=0.

24. v=0 or 1.

25. v=0.

26. o is 1.

27. v=1 and R⁴ is selected from —OH, C₁₋₄alkyl and —NO₂.

28. A compound of any of formulae (I) or (II), or a pharmaceuticallyacceptable salt thereof.

Particular compounds are compounds of formula (I) or formula (II), or apharmaceutically acceptable salt or ester thereof wherein:

X is O;

R¹ and R² are at each occurrence independently selected from halo;R³ and R⁴ are at each occurrence independently selected from H, C₁₋₄alkyl, —OR^(A1), —NO₂ and CN;R⁵ is H or -L¹-R⁷;R⁶ is H or —C(O)R^(A2);L¹ is selected from O and —CH(CN)—;R⁷ is phenyl unsubstituted or substituted with 1, 2, or 3 groupsselected from halo;R^(A1) and R^(A2) are at each occurrence independently selected from Hand C₁₋₄ alkyl;n and p are each independently selected from 0, 1, 2, 3 or 4, with theproviso that n+p is at least 1;t and v are independently selected from 0, 1 and 2.or a pharmaceutically acceptable salt, or ester thereof.

The halogenated salicylanilide may be selected from:

or a pharmaceutically acceptable salt or ester thereof.

The halogenated salicylanilide may be:

or a pharmaceutically acceptable salt or ester thereof.

The halogenated salicylanilide may be a compound selected from Table 1in WO 2008/021088, or a pharmaceutically acceptable salt thereof.

It may be that the halogenated salicylanilide, for example thehalogenated salicylanilide of the formulae (I) or (II) is not thefollowing compounds:

The halogenated salicylanilide may be selected from the group consistingof tetrachlorosalicylanilide, closantel, rafoxanide, oxyclozanide,resorantel, clioxanide, dibromosalan, tribromosalan, brotianide andniclosamide, or a pharmaceutically acceptable salt or ester thereof.

The halogenated salicylanilide may be selected from the group consistingof tetrachlorosalicylanilide, closantel, rafoxanide, oxyclozanide,resorantel, dibromosalan, tribromosalan and niclosamide, or apharmaceutically acceptable salt or ester thereof.

The halogenated salicylanilide may be selected from the group consistingof clioxanide, closantel, oxyclozanide, rafoxanide, tribromosalan or apharmaceutically acceptable salt or ester thereof.

The halogenated salicylanilide may be selected from the group consistingof tetrachlorosalicylanilide, closantel, rafoxanide, oxyclozanide,resorantel, clioxanide, dibromosalan, tribromosalan, brotianide andniclosamide, or a pharmaceutically acceptable salt thereof.

The halogenated salicylanilide may be selected from the group consistingof tetrachlorosalicylanilide, closantel, rafoxanide, oxyclozanide,resorantel, clioxanide, dibromosalan, tribromosalan and niclosamide, ora pharmaceutically acceptable salt thereof.

The halogenated salicylanilide may be selected from the group consistingof niclosamide, clioxanide, closantel, oxyclozanide, rafoxanide andtribromosalan, or a pharmaceutically acceptable salt thereof.

The halogenated salicylanilide may be selected from the group consistingof clioxanide, closantel, oxyclozanide, rafoxanide and tribromosalan, ora pharmaceutically acceptable salt thereof.

The halogenated salicylanilide may be selected from the group consistingof rafoxanide, oxyclozanide and clioxanide, or a pharmaceuticallyacceptable salt thereof.

The halogenated salicylanilide may be selected from the group consistingof clioxanide, closantel, rafoxanide and tribromosalan, or apharmaceutically acceptable salt thereof.

The halogenated salicylanilide may be selected from the group consistingof tetrachlorosalicylanilide, closantel, rafoxanide, oxyclozanide,resorantel, clioxanide, dibromosalan, tribromosalan, brotianide andniclosamide.

The halogenated salicylanilide may be niclosamide, or a pharmaceuticallyacceptable salt or ester thereof, for example the halogenatedsalicylanilide is niclosamide or a pharmaceutically acceptable saltthereof, suitably the halogenated salicylanilide is niclosamide.

The halogenated salicylanilide may be clioxanide, or a pharmaceuticallyacceptable salt or ester thereof, for example the halogenatedsalicylanilide is clioxanide or a pharmaceutically acceptable saltthereof, suitably the halogenated salicylanilide is clioxanide.

The halogenated salicylanilide may be closantel, or a pharmaceuticallyacceptable salt or ester thereof, for example the halogenatedsalicylanilide is closantel or a pharmaceutically acceptable saltthereof, suitably the halogenated salicylanilide is closantel.

The halogenated salicylanilide may be oxyclozanide, or apharmaceutically acceptable salt or ester thereof, for example thehalogenated salicylanilide is oxyclozanide or a pharmaceuticallyacceptable salt thereof, suitably the halogenated salicylanilide isoxyclozanide.

The halogenated salicylanilide may be rafoxanide, or a pharmaceuticallyacceptable salt or ester thereof, for example the halogenatedsalicylanilide is rafoxanide or a pharmaceutically acceptable saltthereof, suitably the halogenated salicylanilide is rafoxanide.

The halogenated salicylanilide may be tribromosalan, or apharmaceutically acceptable salt or ester thereof, for example thehalogenated salicylanilide is tribromosalan or a pharmaceuticallyacceptable salt thereof, suitably particularly the halogenatedsalicylanilide is tribromosalan.

It is to be understood that any of the halogenated salicylanilidesdescribed in this section or elsewhere in the application may be used inany of the treatments described herein.

The halogenated salicylanilide may be administered to the subject usingany suitable route, for example parenterally (for example intravenous,intramuscular or subcutaneous administration), mucosal administration(for example oral or rectal administration. Suitably the halogenatedsalicylanilide is administered orally or rectally. More particularly thehalogenated salicylanilide is administered orally.

The subject or patient in any of the treatments described is suitably ahuman or animal, for example a warm-blooded animal. Particularly thesubject is a human. The subject may be a human aged 65 years or older.The subject may be an animal, e.g. a mammal. In particular, thehalogenated salicylanilide may be for use in the treatment ofClostridium infections in commercial animals such as livestock (e.g.cows, sheep, chickens, pigs, geese, ducks, goats, etc.). Alternatively,halogenated salicylanilide can be used to treat companion animals suchas cats, dogs, horses, etc. The treatment of animals infected a C.difficile with may be particularly effective for preventing spread ofinfection through animal faecal matter to humans or other animals.

Also provided is the use a halogenated salicylanilide, or apharmaceutically acceptable salt or ester thereof for the manufacture ofa medicament for the treatment of an infection in a subject caused byClostridium bacteria.

Also provided is a method of treating an infection caused by Clostridiumbacteria in a subject, the method comprising administering to saidsubject a therapeutically effective amount of a halogenatedsalicylanilide, or a pharmaceutically acceptable salt or ester thereof.

It is to be understood that the use and methods of the above twoparagraphs are applicable to any of the infections, halogenatedsalicylanilides and routes of administration described herein.

Preferred, suitable, and optional features of any one particular aspectof the present invention are also preferred, suitable, and optionalfeatures of any other aspect.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the development of heat-resistant spore count over time forClostridium difficile 7-6011209 in the presence of rafoxanide orfidaxomicin at a concentration of 8-fold above the MIC for rafoxanideand >8-fold above the MIC for fidaxomicin. The control shows the sporecount over time in the Clospore medium used in the study.

DETAILED DESCRIPTION Definitions

Unless otherwise stated, the following terms used in the specificationand claims have the following meanings set out below.

It is to be appreciated that references to “treating” or “treatment”include prophylaxis as well as the alleviation of established symptomsof a condition. “Treating” or “treatment” of a state, disorder orcondition therefore includes: (1) preventing or delaying the appearanceof clinical symptoms of the state, disorder or condition developing in asubject, for example a human, that may be afflicted with or predisposedto the state, disorder or condition but does not yet experience ordisplay clinical or subclinical symptoms of the state, disorder orcondition, (2) inhibiting the state, disorder or condition, i.e.,arresting, reducing or delaying the development of the disease or arelapse thereof (in case of maintenance treatment) or at least oneclinical or subclinical symptom thereof, or (3) relieving or attenuatingthe disease, i.e., causing regression of the state, disorder orcondition or at least one of its clinical or subclinical symptoms.Accordingly in the context of treating infections caused by aClostridium bacteria includes:

(i) the prevention of a disease caused by Clostridium species,particularly Clostridium difficile;(ii) the suppression of a disease caused by Clostridium species,particularly Clostridium difficile:(iii) the relief of symptoms of a disease caused by Clostridium species,particularly Clostridium difficile;iv) the eradication of a non-symptomatic colonization by Clostridiumspecies, particularly Clostridium difficile from an area on or in thebody;(v) the eradication of a Clostridium difficile symptomatic infection;(vi) the eradication a Clostridium species, particularly Clostridiumdimffcile; from an area of the body affected by another disease thatcould enable establishment of an infection more readily, than in anon-disease affected area—e.g. in the intestinal tract;(vii) the suppression of a disease caused a Clostridium infection,particularly Clostridium difficile; from an area of the body affected byanother noninfectious disease that enables establishment of an infectionmore readily, than in a non-disease affected area;(viii) preventing or reducing the risk of transmission or spread of aClostridium infection, particularly Clostridium difficile; or(ix) preventing or reducing the risk of recurrence of a Clostridiuminfection, particularly Clostridium difficile.

A “therapeutically effective amount” means the amount of a compoundthat, when administered to a subject, for example a human, for treatinga disease, is sufficient to effect such treatment for the disease. The“therapeutically effective amount” will vary depending on the compound,the disease and its severity and the age, weight, etc., of the subjectto be treated.

Minimum inhibitory concentration (MIC) is the lowest concentration of anantibacterial that will inhibit the visible growth of a microorganismafter overnight incubation. Minimum inhibitory concentrations areimportant in diagnostic laboratories to confirm resistance ofmicroorganisms to an antimicrobial agent and also to monitor theactivity of new antimicrobial agents. A MIC is generally regarded as themost basic laboratory measurement of the activity of an antimicrobialagent against an organism.

The median lethal dose, LD50 (abbreviation for “lethal dose, 50%”) of atoxin, radiation, or pathogen is the dose required to kill half themembers of a tested population after a specified test duration. LD50figures are frequently used as a general indicator of a substance'sacute toxicity.

Therapeutic index (therapeutic ratio) is defined as the amount of atherapeutic agent causing the therapeutic effect measured as MIC to theamount that causes death in animal studies measured as LD50.

The rate of resistance development is quantified as the frequency ofspontaneous mutants in a population of bacteria that is able to resist agiven concentration of an antibiotic. For example the rate of resistancedevelopment may be 10⁻⁹ if on average 1 cell in 10⁹ cells is able tosurvive a concentration of antibiotic corresponding to 1×MIC incubatedat 37° C. for 48 hours using the method described in Drago et al.Journal of Antimicrobial Chemotherapy, 2005, 56(2), 353 to 359).

In microbiology, colony-forming unit (CFU) is an estimate of the numberof viable bacteria or fungal cells in a sample. Viable is defined as theability to multiply via binary fission under the controlled conditions.

The term “halo” or “halogen” refers to one of the halogens, group 17 ofthe periodic table. In particular the term refers to fluorine, chlorine,bromine and iodine.

The term C_(m)-C_(n) refers to a group with m to n carbon atoms.

The term “C₁-C₆ alkyl” refers to a linear or branched hydrocarbon chaincontaining 1, 2, 3, 4, 5 or 6 carbon atoms, for example methyl, ethyl,n-propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, n-pentyl andn-hexyl. “C₁-C₄ alkyl” similarly refers to such groups containing up to4 carbon atoms.

The term “optionally substituted” refers to either groups, structures,or molecules that are substituted and those that are not substituted.

Where optional substituents are chosen from “one or more” groups it isto be understood that this definition includes all substituents beingchosen from one of the specified groups or the substituents being chosenfrom two or more of the specified groups.

Where a moiety is substituted, it may be substituted at any point on themoiety where chemically possible and consistent with atomic valencyrequirements. The moiety may be substituted by one or more substituents,e.g. 1, 2, 3 or 4 substituents; optionally there are 1 or 2 substituentson a group. Where there are two or more substituents, the substituentsmay be the same or different.

Substituents are only present at positions where they are chemicallypossible, the person skilled in the art being able to decide (eitherexperimentally or theoretically) without undue effort whichsubstitutions are chemically possible and which are not.

Throughout the description and claims of this specification, the words“comprise” and “contain” and variations of them mean “including but notlimited to”, and they are not intended to (and do not) exclude othermoieties, additives, components, integers or steps. Throughout thedescription and claims of this specification, the singular encompassesthe plural unless the context otherwise requires. In particular, wherethe indefinite article is used, the specification is to be understood ascontemplating plurality as well as singularity, unless the contextrequires otherwise.

Features, integers, characteristics, compounds, chemical moieties orgroups described in conjunction with a particular aspect, embodiment orexample of the invention are to be understood to be applicable to anyother aspect, embodiment or example described herein unless incompatibletherewith. All of the features disclosed in this specification(including any accompanying claims, abstract and drawings), and/or allof the steps of any method or process so disclosed, may be combined inany combination, except combinations where at least some of suchfeatures and/or steps are mutually exclusive. The invention is notrestricted to the details of any foregoing embodiments. The inventionextends to any novel one, or any novel combination, of the featuresdisclosed in this specification (including any accompanying claims,abstract and drawings), or to any novel one, or any novel combination,of the steps of any method or process so disclosed.

The reader's attention is directed to all papers and documents which arefiled concurrently with or previous to this specification in connectionwith this application and which are open to public inspection with thisspecification, and the contents of all such papers and documents areincorporated herein by reference.

Suitable or preferred features of any compounds of the present inventionmay also be suitable features of any other aspect.

The invention contemplates pharmaceutically acceptable salts of thehalogenated salicylanilide compounds of the invention. These may includethe acid addition and base salts of the compounds. These may be acidaddition and base salts of the compounds. Suitable acid addition saltsare formed from acids which form non-toxic salts. Suitable base saltsare formed from bases which form non-toxic salts.

Pharmaceutically acceptable salts of the halogenated salicylanilidecompounds may be prepared by for example, one or more of the followingmethods:

(i) by reacting the compound of the invention with the desired acid orbase; or(ii) by converting one salt of the compound of the invention to anotherby reaction with an appropriate acid or base or by means of a suitableion exchange column.

These methods are typically carried out in solution. The resulting saltmay precipitate out and be collected by filtration or may be recoveredby evaporation of the solvent. The degree of ionisation in the resultingsalt may vary from completely ionised to almost non-ionised.

Compounds that have the same molecular formula but differ in the natureor sequence of bonding of their atoms or the arrangement of their atomsin space are termed “isomers”. Isomers that differ in the arrangement oftheir atoms in space are termed “stereoisomers”. Stereoisomers that arenot mirror images of one another are termed “diastereomers” and thosethat are non-superimposable mirror images of each other are termed“enantiomers”. When a compound has an asymmetric center, for example, itis bonded to four different groups, a pair of enantiomers is possible.An enantiomer can be characterized by the absolute configuration of itsasymmetric center and is described by the R- and S-sequencing rules ofCahn and Prelog, or by the manner in which the molecule rotates theplane of polarized light and designated as dextrorotatory orlevorotatory (i.e., as (+) or (−)-isomers respectively). A chiralcompound can exist as either individual enantiomer or as a mixturethereof. A mixture containing equal proportions of the enantiomers iscalled a “racemic mixture”. Where a compound of the invention has two ormore stereocentres any combination of (R) and (S) stereoisomers iscontemplated. The combination of (R) and (S) stereoisomers may result ina diastereomeric mixture or a single diastereoisomer. The compounds ofthe invention may be present as a single stereoisomer or may be mixturesof stereoisomers, for example racemic mixtures and other enantiomericmixtures, and diastereomeric mixtures. Where the mixture is a mixture ofenantiomers the enantiomeric excess may be any of those disclosed above.Where the compound is a single stereoisomer the compounds may stillcontain other diastereoisomers or enantiomers as impurities. Hence asingle stereoisomer does not necessarily have an enantiomeric excess(e.e.) or diastereomeric excess (d.e.) of 100% but could have an e.e. ord.e. of about at least 85%

The compounds of this invention may possess one or more asymmetriccenters; such compounds can therefore be produced as individual (R)- or(S)-stereoisomers or as mixtures thereof. Unless indicated otherwise,the description or naming of a particular compound in the specificationand claims is intended to include both individual enantiomers andmixtures, racemic or otherwise, thereof. The methods for thedetermination of stereochemistry and the separation of stereoisomers arewell-known in the art (see discussion in Chapter 4 of “Advanced OrganicChemistry”, 4th edition J. March, John Wiley and Sons, New York, 2001),for example by synthesis from optically active starting materials or byresolution of a racemic form. Some of the compounds of the invention mayhave geometric isomeric centres (E- and Z-isomers). It is to beunderstood that the present invention encompasses all optical,diastereoisomers and geometric isomers and mixtures thereof that possessactivity against Clostridium bacteria, for example C. difficile.

It is also to be understood that certain compounds of the invention, orsalts or esters thereof, may exist in solvated as well as unsolvatedforms such as, for example, hydrated forms. It is to be understood thatthe invention encompasses all such solvated forms that possess activityagainst Clostridium bacteria, for example C. difficile.

It is also to be understood that the halogenated salicylanilides of theinvention may exhibit polymorphism, and that the invention encompassesall such forms that possess activity against Clostridium bacteria, forexample C. difficile.

It is further to be understood that the halogenated salicylanilide maybe used in the form of suitable pharmaceutically-acceptable pro-drug ofthe compound and that such prodrugs are intended to be encompassed bythe invention. Accordingly, halogenated salicylanilide may beadministered in the form of a pro-drug, that is a compound that isbroken down in the human or animal body to release a compound of theinvention. A pro-drug may be used to alter the physical propertiesand/or the pharmacokinetic properties of a compound of the invention. Apro-drug can be formed when the compound of the invention contains asuitable group or substituent to which a property-modifying group can beattached. Examples of pro-drugs include in vivo cleavable esterderivatives that may be formed at a hydroxy group in a compound.

Accordingly, the present invention includes the halogenatedsalicylanilides as defined hereinbefore when made available by organicsynthesis and when made available within the human or animal body by wayof cleavage of a pro-drug thereof. Accordingly, the present inventionincludes those halogenated salicylanilide compounds that are produced byorganic synthetic means and also such compounds that are produced in thehuman or animal body by way of metabolism of a precursor compound, thatis the halogenated salicylanilide may be a synthetically-producedcompound or a metabolically-produced compound.

A suitable pharmaceutically-acceptable pro-drug of a halogenatedsalicylanilide compound is one that is based on reasonable medicaljudgement as being suitable for administration to the human or animalbody without undesirable pharmacological activities and without unduetoxicity.

Various forms of pro-drug have been described, for example in thefollowing documents:—

a) Methods in Enzymology, Vol. 42, p. 309-396, edited by K. Widder, etal. (Academic Press, 1985);

b) Design of Pro-drugs, edited by H. Bundgaard, (Elsevier, 1985);

c) A Textbook of Drug Design and Development, edited byKrogsgaard-Larsen and H. Bundgaard, Chapter 5 “Design and Application ofPro-drugs”, by H. Bundgaard p. 113-191 (1991);

d) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992);

e) H. Bundgaard, et al., Journal of Pharmaceutical Sciences, 77, 285(1988);

f) N. Kakeya, et al., Chem. Pharm. Bull., 22, 692 (1984);

g) T. Higuchi and V. Stella, “Pro-Drugs as Novel Delivery Systems”,A.C.S. Symposium Series, Volume 14; and

h) E. Roche (editor), “Bioreversible Carriers in Drug Design”, PergamonPress, 1987.

The halogenated salicylanilide may be used in the form of a prodrug ofthe compound for example, an in vivo cleavable ester thereof. An in vivocleavable ester of a compound may be, for example, apharmaceutically-acceptable ester which is cleaved in the human oranimal body to produce the parent compound.

A suitable pharmaceutically-acceptable pro-drug of a halogenatedsalicylanilide that possesses a hydroxy group is, for example, an invivo cleavable ester or ether thereof. An in vivo cleavable ester orether of a compound containing a hydroxy group is, for example, apharmaceutically-acceptable ester or ether which is cleaved in the humanor animal body to produce the parent hydroxy compound. Suitablepharmaceutically-acceptable ester forming groups for a hydroxy groupinclude inorganic esters such as phosphate esters (includingphosphoramidic cyclic esters). Further suitablepharmaceutically-acceptable ester forming groups for a hydroxy groupinclude C₁₋₁₀alkanoyl groups such as acetyl, benzoyl, phenylacetyl andsubstituted benzoyl and phenylacetyl groups, C₁₋₁₀alkoxycarbonyl groupssuch as ethoxycarbonyl, N,N—(C₁₋₆)₂carbamoyl, 2-dialkylaminoacetyl and2-carboxyacetyl groups. Examples of ring substituents on thephenylacetyl and benzoyl groups include aminomethyl, N-alkylaminomethyl,N,N-dialkylaminomethyl, morpholinomethyl, piperazin-1-ylmethyl and4-(C₁₋₄alkyl)piperazin-1-ylmethyl. Suitable pharmaceutically-acceptableether forming groups for a hydroxy group include α-acyloxyalkyl groupssuch as acetoxymethyl and pivaloyloxymethyl groups. Accordinglyreference to a “pharmaceutically acceptable ester” of a compoundencompasses the esters described above.

Halogenated Salicylanilides

The halogenated salicylanilide used in the present invention may be anyof the halogenated salicylanilides described herein, or apharmaceutically acceptable salt thereof, or a pharmaceuticallyacceptable sat thereof, or a pro-drug of any thereof.

Particular halogenated salicylanilides include the compounds of formulae(I) and (II) or a pharmaceutically acceptable salt thereof as describedherein.

More particularly the halogenated salicylanilide is selected from thegroup consisting of tetrachlorosalicylanilide, closantel, rafoxanide,oxyclozanide, resorantel, clioxanide, dibromosalan, tribromosalan andniclosamide.

Niclosamide

In a one embodiment of the invention the halogenated salicylanilide isniclosamide or a pharmaceutically acceptable salt thereof. Niclosamide(2′,5-dichloro-4′-nitrosalicylanilide) exhibits the following acutetoxicity:

LD₅₀, mice, p.o., >5000 mg/kg

LD₅₀, rats, p.o., 5000 mg/kg

LD₅₀, rats, dermal, 2000 mg/kg

LD₅₀, rabbits, p.o., 5000 mg/kg

LD₅₀, cats, p.o., >1000 mg/kg

Niclosamide thus exhibits low toxicity. The compound is poorly solublein water and shows low intestinal absorption. Once in the bloodstreamniclosamide is quickly cleared via the urinary tract or by enzymaticmetabolism in the liver.

Niclosamide Derivatives

It is believed that a number of niclosamide analogs will act in a mannersimilar to niclosamide in the treatment of the Clostridium infectionsdescribed herein. Illustrative niclosamide analogs include, but are notlimited to closantel (CAS #: 57808-65-8), oxyclozanide (CAS #:2277-92-1), rafoxanide (CAS #: 22662-39-1), clioxanide (CAS #:14437-41-3). Other suitable niclosamide analogs include brotianide (CAS#: 23233-88-7), 4′-chloro-3-nitrosalicylanilide,4′-chloro-5-nitrosalicylanilide,2′-chloro-5′-methoxy-3-nitrosalicylanilide,2′-methoxy-3,4′-dinitrosalicylanilide,2′,4′-dimethyl-3-nitrosalicylanilide,2^(l)-chloro-3,4′-dinitrosalicylanilide, 2′-ethyl-3-nitrosalicylanilideand 2′-bromo-3-nitrosalicylanilide; or a pharmaceutically acceptablesalt thereof. Further niclosamide derivatives include those described inWO 2008/021088, particularly those described in Table 1 therein, whichare incorporated herein by reference.

Particular niclosamide analogues include closantel, rafoxanide andoxyclozanide. These compounds are expected to have a suitable toxicityprofile for the use described herein.

Acute Toxicity of Closantel:

LD₅₀, rats, p.o., 262-342 mg/kg (depending on the study), median 302mg/kg

LD₅₀, rats, s.c., 67 mg/kg

LD₅₀, mice, p.o., 331 mg/kg

LD₅₀, mice, i.m., 57 mg/kg

Acute Toxicity of Rafoxanide:

LD₅₀, rats, p.o., 980->2000 mg/kg (depending on the study), median >1490mg/kg

LD₅₀, mice, p.o., 232-300 mg/kg (depending on the study), median 266mg/kg

LD₅₀, rabbits, p.o., 3200 mg/kg

Acute Toxicity of Oxyclozanide.

LD₅₀, rats, p.o., 980-3519 mg/kg (depending on the study), median 2250mg/kg

LD₅₀, mice, p.o., 300 mg/kg

LD₅₀, rabbits, p.o., 3200 mg/kg

Brominated Halogenated Salicylanilides

In another embodiment the halogenated salicylanilide is a brominatedhalogenated salicylanilide, for example 4′,5-dibromosalicylanilide (alsoknown as dibromsalan); 3,5-dibromosalicylanilide (also known asmetabromsalan; and 3,4′,5-tribromosalicylanilide (also known astribromsalan).

Synthesis

The halogenated salicylanilides described herein are known or can besynthesised using known methods. For example using methods analogous tothose described in WO2004/006906. The compounds of the Formula (I)herein may be prepared by coupling an amine of the formula (III) with anacid of formula (IV):

Necessary starting materials are known or can be prepared using standardprocedures of organic chemistry.

Pharmaceutical Compositions

The halogenated salicylanilide may be administered to the subject in theform of a pharmaceutical composition comprising the halogenatedsalicylanilide, or a pharmaceutically acceptable salt or ester thereof,and a pharmaceutically acceptable excipient.

Conventional procedures for the selection and preparation of suitablepharmaceutical formulations are described in, for example,“Pharmaceuticals—The Science of Dosage Form Designs”, M. E. Aulton,Churchill Livingstone, 1988.

The composition may be in a form suitable for oral use (for example astablets, lozenges, hard or soft capsules, aqueous or oily suspensions,emulsions, dispersible powders or granules, syrups or elixirs), fortopical use (for example as creams, ointments, gels, or aqueous or oilysolutions or suspensions), for administration by inhalation (for exampleas a finely divided powder or a liquid aerosol), for administration byinsuffiation (for example as a finely divided powder) or for parenteraladministration (for example as a sterile aqueous or oily solution forintravenous, subcutaneous, intramuscular or intraperitoneal dosing or asa suppository for rectal dosing). Suitably the composition is in a formsuitable for oral administration.

The compositions may be obtained by conventional procedures usingconventional pharmaceutical excipients, well known in the art. Thus,compositions intended for oral use may contain, for example, one or morecolouring, sweetening, flavouring and/or preservative agents.

Dosage

The amount of active ingredient that is combined with one or moreexcipients to produce a single dosage form will necessarily varydepending upon the subject treated and the particular route ofadministration. For example, a formulation in a unit dose form such as atablet or capsule intended for oral administration to humans willgenerally contain, for example, from 0.1 mg to 5 mg, for example from0.5 mg to 5 g, from 0.5 to 1000 mg or from 10 to 500 mg of thehalogenated salicylanilide compounded with an appropriate and convenientamount of excipients which may vary from about 5 to about 98 percent byweight of the total composition.

The size of the dose of the halogenated salicylanilide for the treatmentof the Clostridium infections described herein will naturally varyaccording to the nature and severity of the conditions, the age and sexof the animal or patient and the route of administration, according towell-known principles of medicine.

The halogenated salicylanilide will generally be administered in a doseof about 0.001 to about 75 mg/kg, for example from about 0.013 to about66.7 mg/kg, about 0.5 to about 30 mg/kg or from about 2.5 to about 30mg/kg. The halogenated salicylanilide may be administered within thesedosage ranges to the subject from 1 to 4 times per day. The dosage maybe administered by any suitable route, for example parenterally, orallyor rectally. A particular route of administration which is generallyapplicable to all of the uses of the halogenated salicylanilidesdescribed herein is the oral administration of the halogenatedsalicylanilide to the subject.

The particular dosage regimen used to treat a subject will depend on anumber of factors that may readily be determined, such as the severityof the condition and its responsiveness to initial treatment, but willnormally involve one or more administrations per day on an ongoingbasis. The effective dosage of the pharmaceutical composition of thepresent invention varies from the formulation, administration pathway,age, weight and gender of a human or animal or with a disease caused byClostridium species, particularly Clostridium difficile colonizing orinfecting the intestinal tract of a human or animal having a Clostridiumdifficile infection.

Therapeutic Use

As described hereinbefore the halogenated salicylanilide is used for thetreatment of an infection caused by Clostridium bacteria, particularlyC. difficile. The halogenated salicylanilide may act to kill oreradicate the infection from the subject, thus providing a bactericidaleffect. Alternatively the halogenated salicylanilide may inhibit growthor replication of the bacteria thus producing a bacteriostatic effect.In the context of the present invention, treatment of a conditionencompasses both therapeutic and prophylactic treatment, of either aninfectious or a non-infectious condition, in a subject for example amammal such as a human or animal, but in particular a human. It mayinvolve complete or partial eradication of the condition, removal oramelioration of associated symptoms, arresting subsequent development ofthe condition, and/or prevention of, or reduction of risk of, subsequentoccurrence of the condition.

Generally the halogenated salicylanilide will be administered to asubject experiencing symptoms of a Clostridium infection (for example aC. difficile infection). Accordingly, the halogenated salicylanilide maybe for use in the treatment of a C. difficile associated disease, forexample the halogenated salicylanilide may be for use in the treatmentof a C. difficile associated disease selected from diarrhoea and colitis(including pseudomembranous colitis.

In an alternative embodiment the halogenated salicylanilide is for usein the treatment of a C. difficile in a subject, wherein the subject isasymptomatic. Such uses may be useful to eradicate or inhibit a C.difficile infection in a subject that is at risk of developing C.difficile associated disease. Such subjects could include, for examplesubjects which require surgical procedures in which prophylacticantibiotics may be administered (for example certain orthopaedicsurgery). By eradicating the C. difficile infection prior toadministration of further antibiotics, the risk of antibiotic induceddiarrhoea may be reduced.

Subjects who have previously suffered from an antibiotic induced C.difficile infection may be at a particular risk of developing a C.difficile infection if they are administered antibiotics in the future.Accordingly, in another embodiment the halogenated salicylanilide is foruse in the treatment of a subject prior to the administration of anantibiotic other than the halogenated salicylanilide, wherein thepatient is asymptomatic of a C. difficile infection prior toadministration of the halogenated salicylanilide and where the subjecthas previously suffered from an antibiotic induced a C. difficileinfection.

When the Clostridium infection is an antibiotic induced Clostridiuminfection (for example a C. difficile infection) further administrationof the antibiotic causing the induced infection is suitably halted.Alternatively, the dosage of the antibiotic may be reduced or graduallytapered so as to reduce the risk of exacerbating the antibiotic inducedClostridium infection. Accordingly the halogenated salicylanilide may beadministered to the subject concurrently with another antibiotic beingused to treat a primary infection in the subject. For example it may bethat the halogenated salicylanilide is administered to the subjectconcurrently with an antibiotic being used to treat a primary infectionother than a C. difficile infection. The antibiotic used to treat theprimary infection may, for example, be one or more antibiotics selectedfrom a penicillin, a cephalosporin, a carbapenem, a monobactam (forexample a β-lactam antibiotic), a fusidane, a fluoroquinolone, atetracycline, a glycylcycline, phenicol (for example chloramphenicol), amacrolide, a macrocyclic (for example fidaxomicin), a rifamycin, aketolide, a lincosamide, an oxazolidinone, an aminocyclitol, apolymyxin, a glycopeptide, an aminoglycoside, a lipopeptide, anantimycobacterial, a nitromidazole, bacitracin, mupiricin, apleuromutilin, a rifamycin, a sulphonamide and trimethoprim, or acombination of two or more thereof. However, preferably the halogenatedsalicylanilide is used alone or together with a reduced or tapered doseof the antibiotic(s) responsible for the induced Clostridium infection.More preferably the halogenated salicylanilide is administered to thesubject in the absence of any other antibiotic.

In one embodiment the halogenated salicylanilide is administered to thesubject concurrently with another therapeutic agent in any of thetreatments of the Clostridium infections (particularly the C. difficile)infections described herein. The other therapeutic agent may be, forexample, an antibiotic active against C. difficile, a microbiometherapeutic or faecal transplant, or a vaccine or an antibody therapyfor e.g. C. difficile.

Accordingly in may be that the halogenated salicylanilide isadministered to the subject concurrently with another antibiotic activeagainst a Clostridium infection, particularly a C. difficile infection,other than the halogenated salicylanilide itself. Examples of suchantibiotics include a nitroimidazole, for example metronidazole; abenzimidazole, for example ridinilazole (SMT19969); a glycopeptide, forexample vancomycin; a macrocyclic antibiotic, for example fidaxomicin;an oxazolidinone, for example cadazolid; a lipopeptide, for examplesurothromycin or daptomycin; a glycylcycline, for example tigecycline; aDNA Minor Groove Binder (for example MGB-BP-3) a glycolipodepsipeptide(for example ramoplanin); CRS3123 (a Methionyl-tRNA synthetase (MetRS)inhibitor, Crestone Inc); and a rifamycin such as rifaximin, or acombination of two or more thereof. It may be that the halogenatedsalicylanilide is administered concurrently with metronidazole (forexample concurrently with intravenous metronidazole).

It may be that the halogenated salicylanilide is administered to thesubject concurrently with a vaccine, for example concurrently with avaccine which induces an immune response to C. difficile toxins, forexample toxins A and B (e.g. ACAM-CDIFF, Sanofi, or VLA84 (a fusionprotein containing cell binding domains of Toxins A and B, Valneva), ora vaccine which prevents a C. difficile infection, for examplePF06425090 (Pfizer).

It may be that the halogenated salicylanilide is administered to thesubject concurrently with an antibody therapeutic, for example actoxumaband beziotoxumab or a combination thereof.

It may be that the halogenated salicylanilide is administered to thesubject concurrently with a faecal transplantation or microbiometherapeutics, for example concurrently with a faecal transplant, sporesfrom a non-toxigenic C. difficile strain (e.g. VP-20621); spores frommicrobiome organisms (e.g. SER-109), a microbiota suspension (e.g.RBX2660), a probiotic (e.g. lactobacillus reuterei) or a lactamase, forexample SYN-004.

Reference to administration “concurrently” herein includes the separate,simultaneous or separate administration of the halogenatedsalicylanilide with the other therapy. The halogenated salicylanilidemay be administered to the subject administered by the same or differentroutes of administration, for example oral, intravenously,subcutaneously, or rectally). The halogenated salicylanilide and theother therapy may be administered as a combined preparation; however,generally they will be administered as separate dosage forms to enablethe dose and dosing regimen of each to be tailored accordingly.

The presence of a Clostridium infection (for example a C. difficileinfection) in a subject may be diagnosed using convention methods, forexample infection may be suspected from subject exhibiting symptoms of aC. difficile associated disease. Infection may also be diagnosed usingknown methods for example

-   -   A complete blood count to test for the presence of leukocytosis    -   Measurement of albumin levels to check for hypoalbuminemia,        which may accompany severe disease.    -   Testing for elevated serum lactate levels (≥5 mmol/L), which can        be a sign of severe disease.    -   Stool examination. Stools may be positive for blood in severe        colitis. Faecal leukocytes are present in about half of cases.

Stool assays for C. difficile, may also be used including the following:

-   -   Stool culture: This is a sensitive test. However, the results        are slow and may lead to a delay in the diagnosis.    -   Glutamate dehydrogenase enzyme immunoassay (EIA): This is a very        sensitive test and detects the presence of glutamate        dehydrogenase produced by C. difficile.    -   Real-time polymerase chain reaction (PCR) assay: This test is an        alternative “gold standard” to stool culture. The assay may be        used to detect the C. difficile gene toxins.    -   EIA for detecting toxins A and B produced by C. difficile.

Imaging studies and procedures may also be used to detect infection in asubject. Suitable methods include abdominal computed tomography (CT)scanning. This method is particularly suitable when pseudomembranouscolitis or other complications of CDI are suspected. In subjects withsepsis due to suspected megacolon, abdominal radiography may beperformed instead of CT scanning to establish the presence of megacolon.

The use of halogenated salicylanilides for the treatment of aClostridium infection (for example a C. difficile infection) asdescribed herein is expected to provide a wider therapeutic window thanconventional treatments such as vancomycin, metronidazole orfidaxomicin. Accordingly, the use of halogenated salicylanilides mayresult in reduced side effects compared to known C. difficiletreatments.

Halogenated salicylanilides (e.g. niclosamide) are poorly absorbedfollowing oral administration. Accordingly, the concentration of thehalogenated salicylanilide in the faeces is expected to be high comparedto for example oral administration of similar doses of vancomycin ormetronidazole. A high local concentration of the halogenatedsalicylanilide in the GI tract, especially the colon, would be expectedto enhance the potency and or efficiency of the antibacterial effectlocally in the intestine and colon.

As illustrated in the examples, a number of the halogenatedsalicylanilide tested had similar or higher potencies than vancomycin,metronidazole or fidaxomicin and may therefore be expected to provide anantibacterial effect on Clostridium infections at a similar or lowerdose than conventional treatments such as vancomycin.

Clostridium bacteria (for example C. difficile) are expected to exhibita low frequency of spontaneous mutation in the presence of thehalogenated salicylanilides described herein. Therefore, it is expectedthat the risk of resistance to the halogenated salicylanilide emergingwill be low.

EXAMPLES

In the examples below, the effects of various halogenatedsalicylanilides are compared to vancomycin (a currently approvedcompound for the treatment Clostridium difficile infections).

Example 1 MIC Determinations

C. difficile MICs are determined according to CLSI guideline usingmicrobroth dilution as described in “Methods for AntimicrobialSusceptibility Testing of Anaerobic Bacteria; Approved Standard—EighthEdition” CLSI, ISBN: 1-56238-789-8”, except isovitalex was used in theplace of lysed horse blood.

The media used for the C. difficile MIC tests was Brucella brothsupplemented with hemin (5 μg/ml), vitamin K and Isovitalex (accordingto the manufacturer's instructions). Inoculated plates were incubatedfor 44 to 48 hours at 36° C. under anaerobic conditions (anaerobicchamber or anaerobic jar with gaspack).

The C. difficile strain ATCC 700057 was used as a reference controlduring the C. difficile MIC determinations. This strain has an expectedMIC towards vancomycin of 1 ug/mL.

The results are shown in Tables 2 and 3.

TABLE 2 MIC of clinical isolates of C. difficile against niclosamide andvancomycin C. difficile isolate Niclosamide (ug/mL) Vancomycin(ug/mL)7-6011209 0.06 0.5 7-7150288 0.125 1 7-7152701 0.25 2 7-7154992 0.25 17-5779928 0.25 2 7-6778909 0.25 0.5 7-6870430 0.25 0.5 7-7154712 0.25 27-7104022 0.125 1 7-7153872 0.5 2 7-5085357 0.125 0.5 7-7150997 0.1250.5 7-6008526 0.25 2 7-7124449 0.125 0.5 7-6854508 0.125 0.5 7-73637610.125 0.5 7-7200552 0.25 0.5 7-7150318 0.125 0.5 7-7150628 0.125 17-7149204 0.125 1 7-7154712 0.25 2 7-7116411 0.125 2 7-7151551 0.25 27-7156197 0.25 2 12055 0.125 0.5 12060 0.125 0.5 12061 0.06 0.5 120620.06 0.5 12063 0.06 0.5 12064 0.06 1

Table 2 illustrates that niclosamide has a lower MIC than vancomycinagainst the C. difficile isolates tested.

TABLE 3 C. difficile C. difficile Strain 7-6011209 Strain 12055Compounds MIC (μg/ml) MIC (μg/ml) Clioxanide 0.031 <0.08 Closantel 0.1250.125 Oxyclozanide 0.25 0.25 Rafoxanide <0.08 <0.08 Tribromsalan 0.1250.25 Vancomycin 0.125 0.25

Example 2

Table 4 compares the properties of niclosamide with those of vancomycin,metronidazole, fidaxomicin. The data shown in Table 4 was obtained frompublished data together with data from the examples herein.

TABLE 4 Vancomycin Metronidazole Fidaxomicin Niclosamide ClassGlycopeptide Nitroimidazole Macrolide Halogenated salicylanilide DosingTID, oral TID, oral or IV BID, oral 1-4 times daily, oral MIC90 (μg/mL) 2^(a)  1^(a) 0.5^(a) 0.06-0.25^(b) Highest MIC observed 16^(a) >32^(a)1  0.5 (μg/mL) Spectrum of activity Gram+ Gram+/− Gram+ Gram+ Sideeffects^(c) Bladder pain, Abdominal or Nausea, Nausea, retching,bloating, bloody stomach cramps, vomiting, abdominal pain urine, painfuldizziness, abdominal pain, urination, fever, heartburn. gastrointestinaldry mouth, irregular Spinning sensation. hemorrhage, heartbeat, loss ofTrouble sleeping, anemia, appetite, mood congestion, dry neutropeniachanges, muscle mouth pain or cramps, numbness, rapid weight gain,shortness of breath, tiredness Footnotes: ^(a)ANTIMICROBIAL AGENTS ANDCHEMOTHERAPY, June 2002, p. 1647-1650′ & ‘CID 2012: 55 (Suppl 2) • S143’^(b)Data from Tables 3 and 4 herein. ^(c)Data from product labels.

Example 3: Additional MIC Determinations

The MIC of the halogenated salicylanilides clioxanide, closantel,oxyclozanide, rafoxanide and tribromsalan was determined against 24clinical isolate strains of C. difficile. Fidaxomycin, metronidazole andvancomycin were used as comparator compounds in the study. Thecomparator compounds represent the antibiotics most often used incurrent treatments of C. difficile infections.

Stock solutions of the test compounds and comparators were made in DMSOat a concentration of 1 mg/mL.

Microorganisms

The C. difficile strains used are shown in Table 5:

TABLE 5 Name MLST Name MLST 7-6011209 ST002 7-7363761 ST008 7-7150288ST003 7-7200552 ST017 7-7154992 ST139 7-7150318 ST059 7-6778909 ST0167-7150628 ST034 7-6870430 ST001 7-7149204 ST006 7-7104022 ST1037-7116411 ST005 7-5085357 ST028 7-7150997 ST049 7-7124449 ST0097-6854508 ST013 12055 — 12063 — 12060 — 12064 — 12061 — 12065 — 12062 —12066 —

Culture Medium

C. difficile strains were grown on Brucella blood agar+hemin+vitamin K[1], plates were incubated 44 to 48 hours at 36° C. under anaerobicconditions. Broth cultures were performed in Brucella bouillonsupplemented with Isovitalex [2] according the instructions from thesupplier (BBL). All cultures were performed under anaerobic conditionsin an anaerobic chamber [3].

Antibacterial Activity

The antibacterial activity of the study compounds was determined usingthe following protocol.

-   1. Day 1: bacterial strain is isolated and incubated at 37° C. on    Brucella blood agar+hemin+vitamin K.-   2. Day 2: Inoculate 5 ml of Brucella bouillon supplemented with    Isovitalex (BBI) with one isolated colony in 15 ml Falcon tube and    incubated overnight at 36° C. in anaerobic conditions.-   3. Day 3:    -   Dilute the antibiotics in BBI to their highest concentration (8        μg/ml in 2 ml).    -   Make a series of two fold dilutions in deep well 96 well plates.    -   Transfer 150 μl of the antibiotics solution to 96-well plates.    -   After 5-6 hours, the culture was stopped and OD₆₀₀ was measured.        The culture is diluted to 10 CFU/ml    -   About 1 μl of this diluted culture is added in all wells in        order to have 10 cells per well.    -   Plates are incubated at 44 to 48 hours at 36° C. under anaerobic        conditions.-   4. Day 5: OD₆₀₀ is measured after incubation.    -   Inhibition calculated as follows:

${Inhibition} = {1 - \frac{{{OD}\mspace{14mu} {antibiotic}} - {{OD}\mspace{14mu} {negative}\mspace{14mu} {control}}}{{{OD}\mspace{14mu} {positive}\mspace{14mu} {control}} - {{OD}\mspace{14mu} {negative}\mspace{14mu} {control}}}}$

Results

The MIC values of the tested compounds against the 24 strains of C.difficile are shown in Table 6.

TABLE 6 Strain Clioxanide Closantel Oxyclozanide Rafoxanide TribromsalanFidaxomycin Metronidazole Vancomycin 7-6011209 <0.008 0.016 <0.008<0.008 <0.008 <0.008 0.031 0.031 7-7150288 <0.008 0.031 <0.008 <0.008<0.008 <0.008 0.063 0.5 7-7154992 <0.008 0.063 <0.008 0.016 0.063 <0.0081 0.5 7-6778909 <0.008 0.031 <0.008 <0.008 <0.008 <0.008 0.25 057-6870430 <0.008 0.031 <0.008 <0.008 0.016 0.016 1 0.5 7-7104022 <0.0080.25 <0.008 <0.008 1 <0.008 >8 2 7-5085357 <0.008 0.016 0.016 0.0160.016 <0.008 1 0.5 7-7150997 <0.008 0.016 <0.008 <0.008 0.16 <0.0080.031 <0.008 7-7124449 <0.008 0.25 0.031 0.031 0.063 <0.008 2 0.57-6854508 <0.008 0.25 <0.008 <0.008 0.031 <0.008 1 0.5 7-7363761 <0.008<0.008 7-7200552 <0.008 0.5 0.25 0.063 0.25 <0.008 2 1 7-7150318 <0.0080.63 0.016 <0.008 <0.008 <0.008 1 1 7-7150628 <0.008 0.063 0.31 0.310.031 <0.008 0.5 1 7-7149204 <0.008 0.31 <0.008 <0.008 <0.008 <0.008 0.50.5 7-7116411 0.125 0.25 0.125 0.031 <0.008 2 >16 2 12055 <0.008 0.0630.016 <0.008 0.016 <0.008 1 1 12060 <0.008 0.125 0.031 0.031 0.063<0.008 1 0.5 12061 <0.008 0.063 0.016 0.016 0.016 <0.008 1 0.25 12062<0.008 0.063 <0.008 0.016 <0.008 <0.008 0.125 0.125 12063 <0.008 0.0310.016 <0.008 0.016 <0.008 0.25 0.25 12064 <0.008 0.031 <0.008 <0.008<0.008 <0.008 0.031 0.5 12065 <0.008 0.063 0.031 0.016 0.016 <0.008 10.5 12066 0.063 0.5 0.125 0.063 0.031 <0.008 1 0.5

Table 6 shows that the tested halogenated salicylanilides were activeagainst the tested strains. The most active compounds were clioxanide,rafoxanide and oxyclozanide, which compared favourably with the activityof the comparator compound fidaxomycin. All of the tested halogenatedsalicylanilides generally exhibited lower MIC values than the comparatorcompounds, metronidazole and vancomycin.

REFERENCES

-   [1] H.-P. Schau, “J. F. MacFaddin, Media for    Isolation—Cultivation—Identification—Maintenance of Medical    Bacteria, Volume I. XI+929 S., 163 Abb., 94 Tab. Baltimore,    London 1985. Williams and Wilkins. $90.00. ISBN: 0-683-05316-7,” J.    Basic Microbiol., vol. 26, no. 4, pp. 240-240, 1986.-   [2] L. Pospisil, “[Isovitalex—a chemically definable enricher of    culture media for Neisseria gonorrhoeae],” Ceskoslovenskà Dermatol.,    vol. 46, no. 1, pp. 23-25, February 1971.-   [3] A. N. Edwards, J. M. Suarez, and S. M. McBride, “Culturing and    Maintaining Clostridium difficile in an Anaerobic Environment,” J.    Vis. Exp. JoVE, no. 79, p. e50787, September 2013.

Example 5: Sporulation Study

Clostridium difficile is a spore forming bacteria that causes severediarrhea in healthcare settings. The spore is the infective agent, andis implicated in disease transmission and recurrence. Prevention orinhibition of spore formation may therefore minimise the risk oftransmission and recurrence of infection, particularly in a hospitalenvironment. Currently the main treatments used for the treatment of C.difficile infections are vancomycin, metronidazole, rifaximin andfidaxomicin. It has been shown that fidaxomicin inhibits C. difficilesporulation [1].

The halogenated salicylanilide, rafoxanide was tested assess its abilityto inhibit spore formation. Fidaxomicin was used as a comparator in thestudy.

Methods Bacterial Strain

The C. difficile strain used in the study was 7-6011209, a clinicalisolate from the MLST group ST002.

Antimicrobial Agents

Rafoxanide and fidaxomicin (ex. Sigma-Aldrich) were prepared as 10 mg/mLstock solutions in dimethyl sulfoxide (DMSO). The compounds were dilutedfurther to appropriate concentration in growth media prior to testingfor their effect on sporulation.

Culture Media and Culture Conditions

C. difficile strains were grown and cultured in Brucella bouillonsupplemented with Isovitalex as described above in Example 3.

Sporulation was carried out using Clospore medium [2], comprisingSpecial Peptone Mix (Oxoid) 10 g/L, yeast extract 10 g/L, (NH₄)₂ SO₄ 0.6g/L, MgSO₄ 7H₂O 0.12 g/L, CaCl₂ 2H₂O 0.08 g/L, K₂CO₃ 3.48 g/L, KH₂PO₄2.6 g/L, pH 7.9±0.1.

The germination medium was BHIS medium [3] containing 1 g/L of sodiumtaurocholate. BHIS medium comprises: Brain Heart Infusion 37 g/L, yeastextract 5 g/L, agar 15 g/L, L-cysteine 0.1% (w/v), glucose 0.5% (w/v)and FeSO₄ 0.09% (w/v).

All cultures were performed at 37° C. under anaerobic conditions in ananaerobic chamber as described in Example 3.

Sporulation Kinetics

C. difficile was grown overnight on blood agar plates. One colony wastransferred to 10 mL of Brucella bouillon enriched with Isovitalex andgrown overnight. Clospore medium containing the appropriateconcentration of the test compound was inoculated at 1% with theovernight culture. Samples were withdrawn every 24 hours forquantitation of heat-resistant spores (survivors after incubation at 65°C. for 20 minutes). Spores were serially diluted in 0.09% NaCl andplated on BHIS agar supplemented with 0.1% sodium taurocholate to growthe spores for quantitation.

Concentrations of the test compounds were normalized to the MIC suchthat they were at least 8-fold above the MIC of the respective compound(8-fold for rafoxanide, and >8-fold for fidaxomicin).

Results

The impact of the test compounds on sporulation kinetics is shown inFIG. 1.

The negative control sporulates rapidly reached a value of 2×10⁵ by 24hours and approached its maximum count of approximately 10⁷ by 48 hourssporulation. Rafoxanide, at 8-fold MIC, suppressed formation of sporesthroughout the 96 hour study period. The comparator compoundfidaxomycin, at >8-fold MIC, suppressed formation of spores for thefirst 48 hours of the study, however, increased spore formation comparedto rafoxanide occurred at the 72 and 96 hour time points.

The data illustrated by FIG. 1 shows that rafoxanide suppresses sporeformation more effectively than fidaxomycin at a fixed effect levelrelative to MIC in this study. These results suggest that rafoxanide mayinhibit the shedding of C. difficile spores and as such be effective incontrolling the spread of infection in, for example, a hospitalenvironment. The compound may also be useful in minimising the risk ofrecurrent infections in patients.

REFERENCES

-   [1] F. Babakhani, L. Bouillaut, P. Sears, C. Sims, A. Gomez,    and A. L. Sonenshein, “Fidaxomicin inhibits toxin production in    Clostridium difficile,” J. Antimicrob. Chemother., vol. 68, no. 3,    pp. 515-522, March 2013.-   [2] J. Perez, V. S. Springthorpe, and S. A. Sattar, “Clospore: a    liquid medium for producing high titers of semi-purified spores of    Clostridium difficile,” J. AOAC Int., vol. 94, no. 2, pp. 618-626,    April 2011.-   [3] C. J. Smith, S. M. Markowitz, and F. L. Macrina, “Transferable    tetracycline resistance in Clostridium difficile,” Antimicrob.    Agents Chemother., vol. 19, no. 6, pp. 997-1003, June 1981.

The invention is further illustrated by the following numbered clauses:

1. A halogenated salicylanilide, or a pharmaceutically acceptable saltor ester thereof for use in the treatment of an infection in a subjectcaused by Clostridium bacteria.2. The halogenated salicylanilide for the use of Clause 1 wherein theinfection is caused by Clostridium difficile.3. The halogenated salicylanilide for the use of Clause 2, wherein theinfection is a Clostridium difficile associated disease.4. The halogenated salicylanilide for the use of Clause 3, whereinClostridium difficile associated disease is diarrhoea, colitis (forexample pseudomembranous colitis) or toxic megacolon.5. The halogenated salicylanilide for the use of any of Clauses 1 to 4,wherein the Clostridium infection is an antibiotic induced Clostridiuminfection, wherein the antibiotic is other than a halogenatedsalicylanilide.6. The halogenated salicylanilide for the use of Clause 5, wherein theantibiotic other than a halogenated salicylanilide is selected fromclindamycin, a cephalosporin (for example cefotaxime and ceftaidime),ampicillin, amoxicillin and a quinolone (for example a fluoroquinolone,optionally ciprofloxaxin or levofloxacin).7. The halogenated salicylanilide for the use of any of Clauses 1 to 6,wherein the Clostridium infection has not been treated with anantibiotic prior to administration of the halogenated salicylanilide tothe subject.8. The halogenated salicylanilide for the use of any of Clauses 1 to 6,wherein the subject has a Clostridium infection which has recurredfollowing treatment with an antibiotic other than a halogenatedsalicylanilide.9. The halogenated salicylanilide for the use of Clause 8, whereinClostridium infection has recurred after being treated with anantibiotic selected from metronidazole, vancomycin and fidaxomicin.10. The halogenated salicylanilide for the use of any of Clauses 1 to 6,wherein the Clostridium infection is refractory to a prior antibiotictreatment other than a halogenated salicylanilide.11. The halogenated salicylanilide for the use of Clause 10, wherein theprior antibiotic treatment is selected from metronidazole, vancomycinand fidaxomycin.12. The halogenated salicylanilide for the use of any preceding Clausewherein the infection is caused by the NAP1/027/BI C. difficile strain.13. The halogenated salicylanilide for the use of any preceding Clause,wherein the halogenated salicylanilide is of the formula (I):

wherein

X is O or S;

R¹ and R² are at each occurrence independently selected from halo;R³ and R⁴ are at each occurrence independently selected from H, C₁₋₆alkyl, —OR^(A1), —NO₂ and —CN;R⁵ is H or -L¹-R⁷;R⁶ is H or —C(O)R^(A2);L¹ is selected from a bond, O, S, or —(CR^(A3)R^(B))_(o)—, wherein o is1 or 2;R⁶ is phenyl, unsubstituted or substituted with 1, 2, or 3 groupsselected from halo, C₁₋₄ alkyl, —OR^(A4), —NO₂ and —CN;R^(A1), R^(A2), R^(A3) and R^(A4) are at each occurrence independentlyselected from H and C₁₋₄ alkyl;R^(B) is at each occurrence selected from H, C₁₋₄ alkyl and —CN;n and p are each independently selected from 0, 1, 2, 3 or 4, with theproviso that n+p is at least 1;t and v are independently selected from 0, 1 and 2;or a pharmaceutically acceptable salt, or ester thereof14. The halogenated salicylanilide for the use of Clause 13, wherein Xis O.15. The halogenated salicylanilide for the use of Clause 13 or Clause14, wherein R⁶ is H.16. The halogenated salicylanilide for the use of any of Clauses 13 to15, wherein R³ and R⁴ are at each occurrence independently selected fromH, C₁₋₄ alkyl, —OR^(A1) and —NO₂.17. The halogenated salicylanilide for the use of any of Clauses 13 to16, wherein L¹ is selected from O, —CH₂— and —CH(CN)—.18. The halogenated salicylanilide for the use of any of Clauses 13 to17, wherein R⁷ is phenyl unsubstituted or substituted with 1, 2 or 3groups selected from halo.19. The halogenated salicylanilide for the use of any of Clauses 1 to12, wherein the halogenated salicylanilide is selected from

or a pharmaceutically acceptable salt or ester thereof.20. The halogenated salicylanilide for the use of any of Clauses 1 to12, wherein the halogenated salicylanilide is selected from the groupconsisting of niclosamide, clioxanide, closantel, oxyclozanide,rafoxanide, tribromosalan, or a pharmaceutically acceptable salt orester thereof.21. Use of a halogenated salicylanilide, or a pharmaceuticallyacceptable salt or ester thereof for the manufacture of a medicament forthe treatment of an infection in a subject caused by Clostridiumbacteria.22. A method of treating an infection caused by Clostridium bacteria ina subject, the method comprising administering to said subject aneffective amount of a halogenated salicylanilide, or a pharmaceuticallyacceptable salt or ester thereof.23. The halogenated salicylanilide for the use of any of Clauses 1 to20, the use of Clause 21 or the method of Clause 22, wherein thehalogenated salicylanilide is orally administered to the subject.24. The halogenated salicylanilide for the use of any of Clauses 1 to20, the use of Clause 21 or the method of Clause 22, wherein the subjectis a human or warm blooded animal, optionally wherein the subject is ahuman.25. The halogenated salicylanilide for the use of any of Clauses 1 to20, the use of Clause 21 or the method of Clause 22, wherein the subjectis a human aged 65 years or older

1. A method of treating an infection caused by Clostridium difficilebacteria in a subject, the method comprising administering to saidsubject an effective amount of a halogenated salicylanilide, or apharmaceutically acceptable salt or ester thereof, wherein thehalogenated salicylanilide is of the formula:

wherein R¹ and R² are each independently halo; L¹ is selected from thegroup consisting of a bond and O; R⁷ is phenyl, unsubstituted orsubstituted with 1 or 2 groups each independently selected from thegroup consisting of halo and C₁₋₄ alkyl; n is 1 or 2; p is 0 or
 1. 2.The method of claim 1, wherein R¹ is independently selected from I andCl.
 3. The method of claim 1, wherein n is 2 and R¹ is independentlyselected from I and Cl.
 4. The method of claim 1, wherein n is 2 and R¹is Cl.
 5. The method of claim 1, wherein L¹ is O and R⁷ is phenylsubstituted with 1 halo.
 6. The method of claim 1, wherein L¹ is O andR⁷ is phenyl substituted with 1 Cl.
 7. The method of claim 1, wherein pis
 0. 8. The method of claim 1, wherein: R¹ is Cl; L¹ is O; R⁷ is phenylsubstituted with 1 Cl. n is 2; and p is
 0. 9. The method of claim 1,wherein the Clostridium difficile infection is associated with a diseaseselected from the group consisting of diarrhoea, colitis,pseudomembranous colitis and toxic megacolon.
 10. The method of claim 1,wherein the Clostridium difficile infection is an antibiotic inducedClostridium difficile infection, wherein the antibiotic which inducedthe infection is other than the halogenated salicylanilide.
 11. Themethod of claim 10, wherein the antibiotic which induced the infectionis selected from clindamycin, a cephalosporin, cefotaxime, ceftazidime,ampicillin, amoxicillin, a quinolone, a fluoroquinolone, ciprofloxaxinand levofloxacin.
 12. The method of claim 1, wherein the Clostridiumdifficile infection is induced by a gastric acid suppressive agent. 13.The method of claim 1, wherein the Clostridium difficile is resistant toan antibiotic agent other than the halogenated salicylanilide.
 14. Themethod of claim 13, wherein the Clostridium difficile is a Clostridiumdifficile strain that is resistant to an antibiotic agent selected frommetronidazole, vancomycin, fidaxomicin and a rifamycin.
 15. The methodof claim 1, wherein the Clostridium difficile infection has not beentreated with an antibiotic prior to administration of the halogenatedsalicylanilide to the subject.
 16. The method of claim 1, wherein thesubject has a recurrent Clostridium difficile infection.
 17. The methodof claim 16, wherein the recurrent Clostridium difficile infection hasrecurred following prior treatment with an antibiotic other than thehalogenated salicylanilide.
 18. The method of claim 16, wherein theClostridium difficile infection has recurred after being treated with anantibiotic selected from metronidazole, vancomycin, fidaxomicin and arifamycin.
 19. The method of claim 1, wherein treatment of the subjectwith the halogenated salicylanilide, or a pharmaceutically acceptablesalt or ester thereof, prevents or inhibits sporulation of C. difficilein the subject.
 20. The method of claim 1, wherein the halogenatedsalicylanilide, or a pharmaceutically acceptable salt or ester thereof,is orally administered to the subject.
 21. The method of claim 1,wherein the subject is a human.